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Summary
Background The COVID-19 pandemic has placed unprecedented strain on health-care systems. Frailty is being used in 
clinical decision making for patients with COVID-19, yet the prevalence and effect of frailty in people with COVID-19 is 
not known. In the COVID-19 in Older PEople (COPE) study we aimed to establish the prevalence of frailty in patients 
with COVID-19 who were admitted to hospital and investigate its association with mortality and duration of hospital 
stay.
Methods This was an observational cohort study conducted at ten hospitals in the UK and one in Italy. All adults 
(≥18 years) admitted to participating hospitals with COVID-19 were included. Patients with incomplete hospital 
records were excluded. The study analysed routinely generated hospital data for patients with COVID-19. Frailty was 
assessed by specialist COVID-19 teams using the clinical frailty scale (CFS) and patients were grouped according to 
their score (1–2=fit; 3–4=vulnerable, but not frail; 5–6=initial signs of frailty but with some degree of independence; 
and 7–9=severe or very severe frailty). The primary outcome was in-hospital mortality (time from hospital admission 
to mortality and day-7 mortality).
Findings Between Feb 27, and April 28, 2020, we enrolled 1564 patients with COVID-19. The median age was 74 years 
(IQR 61–83); 903 (57·7%) were men and 661 (42·3%) were women; 425 (27·2%) had died at data cutoff (April 28, 2020). 
772 (49·4%) were classed as frail (CFS 5–8) and 27 (1·7%) were classed as terminally ill (CFS 9). Compared with 
CFS 1–2, the adjusted hazard ratios for time from hospital admission to death were 1·55 (95% CI 1·00–2·41) for 
CFS 3–4, 1·83 (1·15–2·91) for CFS 5–6, and 2·39 (1·50–3·81) for CFS 7–9, and adjusted odds ratios for day-7 mortality 
were 1·22 (95% CI 0·63–2·38) for CFS 3–4, 1·62 (0·81–3·26) for CFS 5–6, and 3·12 (1·56–6·24) for CFS 7–9.
Interpretation In a large population of patients admitted to hospital with COVID-19, disease outcomes were better 
predicted by frailty than either age or comorbidity. Our results support the use of CFS to inform decision making 
about medical care in adult patients admitted to hospital with COVID-19.
Funding None.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction
The ongoing COVID-19 pandemic is caused by severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
which was first documented in China in late 2019.1 An 
increasing number of case series are being published that 
describe the clinical features and predictors of mortality 
in people with COVID-19.2–4 In these studies, older age 
has consistently been shown to be associated with poor 
outcomes, with increasing mortality linked to increasing 
age.5
Age is an attractive prognostic tool because it is easy to 
measure. However, we previously showed that on the 
individual level, age alone has little prognostic use.6,7 A 
simple prognostic factor is needed to inform acute 
decisions on COVID-19 care pathways and one potential 
marker is frailty.8
In the UK, the National Institute for Clinical Excellence 
(NICE) released a rapid COVID-19 guideline recom-
mending the use of the clinical frailty score (CFS)9 
in discussions with patients regarding admission to 
intensive care units.8 The guideline was based on patient 
group recommendations; however, it came under 
criticism by the National Health Service Specialist 
Clinical Frailty Network who recommended that CFS 
should not be used in isolation but that the clinical 
discussions must be taken in conjunction with patient 
and carer wishes, and that the guidance might not apply 
to younger people or those with disabilities, in whom 
CFS has not been validated. There remains an important 
research gap with regards to supporting the use of CFS 
in the acute management of the ongoing pandemic.
Frailty is defined as “a medical syndrome with multiple 
causes and contributors that is characterised by dimin-
ished strength, endurance, and reduced physio logic 
function that increases an individual’s vulnera bility for 
developing increased dependency and/or death”.10 The 
prevalence of frailty in middle-aged and older patients 
varies according to the method of identifying frailty and 
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the specific population but is estimated to be about 
40%.11,12 The likelihood of being frail increases with age, 
but can occur in younger adults.13 In addition, there is 
substantial evidence that frailty equates to worse patient 
outcomes in those admitted to hospital, including 
medical and surgical admissions as well as patients 
requiring intensive care.14 As a result it is becoming 
widely used as a trigger for specialist resource allocation, 
pathway decision aid, and shared decision making.15,16
No information is available on the prevalence of frailty 
in patients admitted to hospital with COVID-19 or how it 
affects their outcomes. Such evidence will aid and 
support physicians in decision making with this complex 
group of patients. Additionally, it will provide an evidence 
base to support the NICE rapid COVID recommendation 
of CFS score being used to guide admission to critical 
care.
The aim of the COVID-19 in Older PEople (COPE) study 
was to establish the prevalence of frailty in patients with 
COVID-19 who were admitted to hospital and investigate 
its influence on mortality and duration of hospital stay.
Methods
Study design
The COPE study is a multicentre European observational 
cohort study conducted at 11 hospitals in the UK and Italy. 
Authority in the UK to conduct the study was granted by 
the Health Research Authority (20/HRA/1898), and in 
Italy by the ethics committee of University Hospital of 
Modena Policlinico (369/2020/OSS/AOUMO). Ethical 
approval was such that formal written consent from 
participants was not required. This manu script follows 
the STROBE statement for reporting of cohort studies.
Participants
All patients aged 18 years or older admitted to the parti-
cipating hospitals with a diagnosis of COVID-19 were 
included. Diagnostic criteria were laboratory-confirmed 
SARS-CoV-2-positive swabs or a clinical diagnosis made 
by the parent clinical team and based on signs, symptoms, 
or radiology consistent with COVID-19. Patients were 
excluded during data analysis if their hospital records 
were incomplete. No other exclusion criteria were applied. 
Clinical teams at each site screened inpatient admission 
lists for eligibility. Screening logs of eligible participants 
were retained at each site.
Data collection
To allow rapid data collection for this time-sensitive topic, 
this study used an existing network of clinical centres with 
experience in collecting frailty data using the CFS for 
academic and service assessment purposes, with the 
addition of one Italian site. Data were collected across 
ten centres in the UK (Ysbyty Ystrad Fawr [Caerphilly], 
Royal Gwent Hospital [Newport], Nevill Hall Hospital 
[Abergavenny], Southmead Hospital Bristol [Bristol], 
Aberdeen Royal Infirmary [Aberdeen], Royal Alexandra 
Hospital [Paisley], Royal Inverclyde Hospital [Inverclyde], 
Salford Royal Infirmary [Salford], Glasgow Royal Infirmary 
[Glasgow], and the University Hospital of Wales [Cardiff]) 
and one Italian hospital (University Hospital of Modena 
Policlinico [Modena]). All hospitals admit acutely unwell 
people with COVID-19 except two sites (Ysbyty Ystrad 
Fawr and Glasgow Royal Infirmary) that receive self-
referred patients and patients triaged by paramedic staff. 
For all sites, assessment of frailty using the CFS was 
routinely collected data (as per NICE recommendations). 
In each site the assessment of CFS in patients with 
COVID-19 was overseen by specialist COVID-19 mega-
teams—in the UK, a megateam con sisted of a consultant 
geriatrician, an emergency physician, and an intensive 
care consultant. For all patients with COVID-19 admitted 
to hospital, CFS was documented in a dedicated section 
on each patient’s admission booklet. CFS is a quick to use 
assessment tool and is most reliably performed by 
geriatricians who use it routinely.
The study analysed routinely generated hospital data 
for patients with COVID-19. A standardised case report 
format was used for recording data collected prospectively 
and supplemented by patient records and drug pres-
cription charts. Before participating, all study personnel 
completed specific data collection training. It was also a 
Research in context
Evidence before this study
We searched PubMed, medRxiv, CINAHL, and Web of Science on 
April 30, 2020, using the search terms ”frailty” and 
“coronavirus2”. We searched for primary research and reviews 
published up to April 30, 2020, with no language restrictions. 
Despite the importance of frailty in UK national COVID-19 
policy, our initial scoping literature review identified no 
published data at scale regarding frailty and outcomes in 
COVID-19.
Added value of this study
These data provide the first prevalence estimate of frailty in an 
adult patient population admitted to hospital with COVID-19. 
Using an established frailty scale (the clinical frailty scale [CFS]), 
we showed that patients classed as frail by the CFS are more 
likely to die from COVID-19 and are discharged from hospital 
less quickly than those who are not frail. These findings were 
independent of age and comorbidities.
Implications of all the available evidence
Clinical decisions are being made regarding the management of 
people with COVID-19 on the basis of their frailty status, using 
the clinical frailty scale. Our findings provide evidence to 
support those decisions.
For the older persons surgical 
outcomes collaborative see 
www.opsoc.eu
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prerequisite for study personnel to familiarise themselves 
with the process of frailty assessment through use of an 
open-access online resource.17 Training was supervised at 
a local level by the site’s principal investigator. Local data 
protection policy was followed in order to record data 
securely at each site. Subsequently, each site transferred 
anonymised data to King’s College London for statistical 
analysis.
Demographic data for age and sex were collected. 
Variables for analysis were selected from those used in 
recent COVID studies, which appear to be prognostic 
indicators.1,2,4,18 These were clinical diagnosis of coronary 
artery disease, diabetes, and hypertension; smoking status 
(never, previous, or current); and blood biomarkers 
(C-reactive protein, with >40 mg/dL considered abnormal; 
albumin, with ≤34 g/L considered hypoalbuminaemia; 
and estimated glomerular filtration rate [eGFR] , with 
<60 mL/min per 1·73 m² considered moderate or worse 
renal function).
The CFS (appendix p 6) was used to assess frailty. It 
bases the frailty assessment on how a patient was 2 weeks 
before hospital admission. The CFS is an ordinal 
hierarchical scale that numerically ranks frailty from 
1 to 9, with a score of 1 being very fit, 2 well, 3 managing 
well, 4 vulnerable, 5 mildly frail, 6 moderately frail, 
7 severely frail, 8 very severely frail, and 9 terminally ill. 
We did not anticipate that there would be adequate 
number of events for each score so scores were 
grouped 1–2 (fit), 3–4 (becoming vulnerable, but not 
frail), 5–6 (initial signs of frailty but with some degree of 
independence), and 7–9 (severe or very severe frailty) for 
the purposes of the analyses. These groups were selected 
to fit with the clinical descriptions outlined in the CFS 
and we deemed them to be reasonable groupings of 
severity of frailty.
Outcomes
The primary outcome was mortality (time from hospital 
admission to mortality and day-7 mortality). The secon-
dary outcome was time from hospital admission to 
discharge. For patients diagnosed with COVID-19 while 
an inpatient (hospital acquired or nosocomial infection), 
the date of diagnosis was used in lieu of the date of 
All patients 
(n=1564)
Dead 
(n=425)
Alive 
(n=1139)
Sites
Hospital A 115 (7·4%) 15 (13·0%) 100 (87·0%)
Hospital B 50 (3·2%) 14 (28·0%) 36 (72·0%)
Hospital C 153 (9·8%) 34 (22·2%) 119 (77·8%)
Hospital D 43 (2·7%) 10 (23·3%) 33 (76·7%)
Hospital E 123 (7·9%) 15 (12·2%) 108 (87·8%)
Hospital F 154 (9·8%) 23 (14·9%) 131 (85·1%)
Hospital G 112 (7·2%) 36 (32·1%) 76 (67·9%)
Hospital H 246 (15·7%) 108 (43·9%) 138 (56·1%)
Hospital I 380 (24·3%) 126 (33·2%) 254 (66·8%)
Hospital J 179 (11·5%) 43 (24·0%) 136 (76·0%)
Hospital K 9 (0·6%) 1 (11·1%) 8 (88·9%)
Age, years
<65 488 (31·2%) 55 (11·3%) 433 (88·7%)
65–79 535 (34·2%) 168 (31·4%) 367 (68·6%)
≥80 541 (34·6%) 202 (37·3%) 339 (62·7%)
Sex
Female 661 (42·3%) 170 (25·7%) 491 (74·3%)
Male 903 (57·7%) 255 (28·2%) 648 (71·8%)
Smoking status
Never smokers 814 (52·0%) 205 (25·2%) 609 (74·8%)
Ex-smokers 603 (38·6%) 185 (30·7%) 418 (69·3%)
Current smokers 121 (7·7%) 26 (21·5%) 95 (78·5%)
Missing 26 (1·7%) 9 (34·6%) 17 (65·4%)
Diabetes
No 1144 (73·1%) 295 (25·8%) 849 (74·2%)
Yes 415 (26·5%) 128 (30·8%) 287 (69·2%)
Missing 5 (0·3%) 2 (40·0%) 3 (60·0%)
Hypertension
No 755 (48·3%) 184 (24·4%) 571 (75·6%)
Yes 804 (51·4%) 238 (29·6%) 566 (70·4%)
Missing 5 (0·3%) 3 (60·0%) 2 (40·0%)
(Table 1 continues in next column)
All patients 
(n=1564)
Dead 
(n=425)
Alive 
(n=1139)
(Continued from previous column)
Coronary artery disease
No 1214 (77·6%) 290 (23·9%) 924 (76·1%)
Yes 345 (22·1%) 132 (38·3%) 213 (61·7%)
Missing 5 (0·3%) 3 (60·0%) 2 (40·0%)
Increased C-reactive protein (>40 mg/dL)
No 439 (28·1%) 66 (15·0%) 373 (85·0%)
Yes 1125 (71·9%) 359 (31·9%) 766 (68·1%)
Missing 32 (2·0%) 12 (37·5%) 20 (62·5%)
Impaired renal function (eGFR <60 mL/min per 1·73 m²)
No 980 (63·7%) 202 (20·6%) 778 (79·4%)
Yes 570 (36·4%) 217 (38·1%) 353 (61·9%)
Missing 14 (0·9%) 6 (42·9%) 8 (57·1%)
Clinical frailty score
1: very fit 91 (5·8%) 7 (7·7%) 84 (92·3%)
2: fit 197 (12·6%) 22 (11·2%) 175 (88·8%)
3: managing well 287 (18·4%) 55 (19·2%) 232 (80·8%)
4: vulnerable 185 (11·8%) 52 (28·1%) 133 (71·9%)
5: mildly frail 182 (11·6%) 50 (27·5%) 132 (72·5%)
6: moderately frail 251 (16·0%) 84 (33·5%) 167 (66·5%)
7: severely frail 260 (16·6%) 96 (36·9%) 164 (63·1%)
8: very severely frail 79 (5·1%) 44 (55·7%) 35 (44·3%)
9: terminally ill 27 (1·7%) 12 (44·4%) 15 (55·6%)
Missing 5 (0·3%) 3 (60·0%) 2 (40·0%)
Percentages for the dead and alive columns use the total for each row 
(from the all patients column) as the denominator. eGFR=estimated 
glomerular filtration rate.
Table 1: Demographics and frailty, by in-hospital mortality
See Online for appendix
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admission. Patients still in hospital at the latest follow-up 
point were censored for the time-to-mortality analysis. 
Patients that died were censored at the date of death for 
the time-to-discharge analysis. Patients still in hospital at 
latest follow-up with fewer than 7 days of follow-up data 
were excluded from the day-7 analysis.
Other prespecified outcomes were long-term mortality 
(day-90 mortality and time from hospital admission 
to mortality); day-30 readmission; and the effect of drug 
classes, nosocomial infection, and deprivation on disease 
outcomes. These are not analysed here and will be 
reported in a future publication.
Statistical analysis
The original protocol planned to include a minimum of 
500 patients. We estimated a minimum of 30% mortality 
in those that were frail, and 20% in those not frail (hazard 
ratio [HR] of 0·60). To detect this difference with 
80% power and with a 5% significance, at least 
500 patients were to be included. The sample size was 
increased to assess CFS categorised into four groups 
(rather than frail vs not frail).19
The first primary outcome measure (time to mortality), 
and the secondary outcome (time to discharge) were 
analysed with mixed-effects multivariable Cox 
proportional baseline hazards models. The analysis was 
fitted with a random effect20 to account for variation 
occurring at each hospital site, and adjusted for patient 
age group (<65 years, 65–79 years, and ≥80 years), sex 
(female or male), smoking status (never smoker, ex-
smoker, or current smoker), C-reactive protein 
(>40 mg/dL or ≤40 mg/dL), diabetes (yes or no), 
hypertension (yes or no), coronary artery disease (yes or 
no), and eGFR (<60 mL/min per 1·73 m² or ≥60 mL/min 
per 1·73 m²). Both a crude HR, and adjusted HR were 
estimated with associated 95% CIs. The baseline 
proportionality assumption was tested fitting log–log 
residuals. Each time-to-event analysis was reported with 
a Kaplan-Meier survival plot.
The primary outcome measure of day-7 mortality was 
analysed using a mixed-effects multivariable logistic 
regression, fitting each hospital as a random intercept 
effect, and adjusted with covariates consistent with the 
primary outcome. Both crude odds ratio (OR) and 
adjusted OR were presented with associated 95% CIs. 
Missing data were explored for patterns of missingness. 
We did exploratory subgroup analyses to explore the 
effect of frailty (CFS ≤4 or CFS ≥5) within each of 
the demographic and comorbidity subgroups of patients. 
Analyses were performed using Stata version 15. 
Kaplan-Meier survival plots were visualised in R.
Role of the funding source
There was no funding source for this study. The corres-
ponding author had full access to all the data in the study 
and had final responsibility for the decision to submit for 
publication.
Crude HR (95% CI)* p value Adjusted HR† 
(95% CI)‡
p value
Age, years
<65 1 (ref) ·· 1 (ref) ··
65–79 3·30 (2·40–4·55) <0·0001 2·58 (1·82–3·64) <0·0001
≥80 4·05 (2·95–5·57) <0·0001 2·92 (2·02–4·22) <0·0001
Sex
Female 1 (ref) ·· 1 (ref) ··
Male 0·99 (0·81–1·21) 0·93 1·07 (0·85–1·32) 0·56
Smoking status
Never 1 (ref) ·· 1 (ref) ··
Ex-smokers 1·20 (0·98–1·47) 0·079 0·95 (0·77–1·18) 0·67
Current smokers 0·84 (0·55–1·29) 0·43 0·91 (0·59–1·42) 0·69
Increased C-reactive 
protein (>40 mg/dL)
2·22 (1·69–2·92) <0·0001 2·61 (1·97–3·45) <0·0001
Patients with diabetes 1·12 (0·90–1·39) 0·30 1·03 (0·82–1·29) 0·83
Patients with coronary 
artery disease
1·57 (1·26–1·95) <0·0001 1·19 (0·94–1·49) 0·83
Patients with hypertension 1·24 (1·01–1·51) 0·036 0·95 (0·77–1·18) 0·66
Impaired renal function 
(eGFR <60 mL/min per 
1·73 m²)
1·93 (1·58–2·35) <0·0001 1·43 (1·16–1·77) 0·0007
Clinical frailty scale
1–2 1 (ref) ·· 1 (ref) ··
3–4 2·25 (1·47–3·45) <0·0002 1·55 (1·00–2·41) 0·052
5–6 3·12 (2·05–4·76) <0·0001 1·83 (1·15–2·91) 0·011
7–9 4·41 (2·90–6·71) <0·0001 2·39 (1·50–3·81) <0·0002
eGFR=estimated glomerular filtration rate. HR=hazard ratio. *n=1520; 44 patients were not included in the analysis 
because of patient death or discharge on the day of admission. †The multivariable mixed-effects Cox regression was 
adjusted for age group, sex, smoking, C-reactive protein, diabetes, coronary artery disease, hypertension, renal 
function, and the clinical frailty scale. ‡n=1500; 20 further patients were not included in this analysis because of 
missing covariate data.
Table 2: Time to mortality
Figure 1: Overall survival by CFS category
CFS=clinical frailty score.
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Results
Between Feb 27 and April 28, 2020, we screened 
1707 participants from general medical, surgical, geriatric 
wards, respiratory wards. 143 participants were excluded. 
The reasons for exclusion were no clinical record found 
(n=66); no positive laboratory or clinical diagnosis found 
(n=61); and unable to access the patient record (n=16). The 
study included 1564 participants (table 1), of whom 
1410 (90·2%) were recruited in the UK and 154 (9·8%) in 
Italy. 1500 (95·9%) patients were diagnosed via laboratory 
testing and 64 (4·1%) via clinical diagnosis only. Complete 
data were available for 1500 (95·9%) of included patients, 
and all outcomes were completed for all patients. 
26 patients had missing smoking status and these were 
imputed as never smokers; 32 patients had missing 
C-reactive protein status and these were imputed as 
C-reactive protein less than 40 mg/dL; 14 patients had 
missing eGFR data and these were not imputed. A 
maximum of five patients had missing data for each of the 
remaining covariates. Given the minimal degree of 
missing data, a complete case population was used within 
each analysis. Data were collected between Feb 27 and 
April 28, 2020 (UK data collection began on March 6).
The study population median age was 74 years 
(IQR 61–83; range 20–101); 903 (57·7%) of 1564 were 
men and 661 (42·3%) were women (table 1). 772 (49·4%) 
were classed as frail (CFS 5–8) and 27 (1·7%) were classed 
as terminally ill (CFS 9). At data cutoff (April 28, 2020), 
425 (27·2%) of patients had died, with rates of 11·1–43·9% 
across the 11 hospitals. Median survival time for 
those that died was 7 days (IQR 4–11) after admission. 
727 patients were discharged. The median duration of 
hospital stay for those discharged was 9 days (IQR 5–15). 
The distribution of cases and mortality across age groups 
and CFS is shown in the appendix (p 1); increased frailty 
was associated with mortality at all ages.
Frailty was associated with both mortality and time to 
discharge from hospital after adjustment for age, sex, 
smoking status, and other comorbidities, exhibiting 
worsening clinical outcome with increasing frailty 
(tables 2, 3).
The crude HR for time from hospital admission to 
mortality was 2·25 (95% CI 1·47–3·45; p<0·0002) for 
CFS 3–4, 3·12 (2·05–4·76; p<0·0001) for CFS 5–6, and 
4·41 (2·90–6·71; p<0·0001) for CFS 7–9, all compared with 
CFS 1–2 (table 2, figure 1). Compared with patients aged 
younger than 65 years, the crude HR was 3·30 (95% CI 
2·40–4·55; p<0·0001) for those aged 65–79 years and 4·05 
(2·95–5·57; p<0·0001) for those aged 80 years or older 
(table 2, figure 2). Coronary artery disease, reduced renal 
function, increased C-reactive protein, and hypertension 
were also associated with mortality. After adjusting for the 
other covariates, increasing frailty was generally associated 
with increased mortality. Compared with CFS 1–2, the 
adjusted HRs were, 1·55 (95% CI 1·00–2·41; p=0·052) for 
CFS 3–4, 1·83 (1·15–2·91; p=0·011) for CFS 5–6, and 2·39 
(1·50–3·81; p<0·0002) for CFS 7–9. Older age, increased Figure 2: Overall survival by age
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Crude HR (95% CI)* p value Adjusted HR† 
(95% CI)‡
p value
Age, years
<65 1 (ref) ·· 1 (ref) ··
65–79 0·74 (0·62–0·88) 0·0006 0·82 (0·68–1·00) 0·047
≥80 0·56 (0·46–0·68) <0·0001 0·62 (0·49–0·79) <0·0001
Sex
Female 1 (ref) ·· 1 (ref) ··
Male 1·03 (0·89–1·21) 0·67 0·94 (0·80–1·10) 0·42
Smoking status
Never 1 (ref) ·· 1 (ref) ··
Ex-smokers 0·90 (0·77–1·05) 0·19 0·95 (0·81–1·12) 0·54
Current smokers 1·05 (0·78–1·43) 0·74 0·97 (0·71–1·32) 0·84
Increased C-reactive 
protein (>40 mg/dL)
0·84 (0·71–0·98) 0·028 0·73 (0·61–0·86) <0·0002
Patients with diabetes 0·89 (0·75–1·06) 0·18 0·93 (0·77–1·12) 0·43
Patients with coronary 
artery disease
0·91 (0·74–1·10) 0·33 1·10 (0·90–1·36) 0·36
Patients with hypertension 0·86 (0·75–1·00) 0·056 0·93 (0·79–1·09) 0·36
Impaired renal function 
(eGFR <60 mL/min per 
1·73 m²)
0·78 (0·66–0·92) 0·0031 0·95 (0·79–1·14) 0·58
Clinical frailty scale
1–2 1 (ref) ·· 1 (ref) ··
3–4 0·87 (0·71–1·05) 0·15 0·94 (0·77–1·16) 0·58
5–6 0·61 (0·49–0·76) <0·0001 0·70 (0·54–0·91) 0·0084
7–9 0·56 (0·44–0·72) <0·0001 0·66 (0·50–0·87) 0·0035
eGFR=estimated glomerular filtration rate. HR=hazard ratio. *n=1520; 44 patients were not included in the analysis 
because of patient death or discharge on the day of admission. †The multivariable mixed-effects Cox regression was 
adjusted for age group, sex, smoking, C-reactive protein, diabetes, coronary artery disease, hypertension, renal 
function, and the clinical frailty scale. ‡n=1500; 20 further patients were not included in this analysis because of 
missing covariate data. 
Table 3: Time from hospital admission to discharge
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C-reactive protein, and impaired renal function were also 
associated with mortality in adjusted analyses (table 2). 
Residual log–log plots did not offer any indication of any 
breach of proportionality. Similar results were recorded for 
the coprimary outcome of day-7 mortality for CFS 7–9 
(appendix p 2). The adjusted ORs for day-7 mortality were 
1·22 (95% CI 0·63–2·38; p=0·56) for CFS 3–4, 1·62 
(0·81–3·26; p=0·17) for CFS 5–6, and 3·12 (1·56–6·24; 
p<0·0012) for CFS 7–9, all compared with CFS 1–2.
The time from hospital admission to discharge analysis 
showed that CFS 5–6 and 7–9 were associated with a 
longer duration of hospital stay than CFS 1–2. Compared 
with CFS 1–2, the adjusted HRs were 0·94 (95% CI 
0·77–1·16; p=0·58) for CFS 3–4, 0·70 (0·54–0·91; 
p=0·0084) for CFS 5–6, and 0·66 (0·50–0·87, p=0·0035) 
for CFS 7–9 (figure 3, table 3). In addition to frailty, age 
65 years and older and increased C-reactive protein were 
associated with longer hospital stay.
The subgroup analyses showed a consistent finding 
with the main analyses, that frail patients (CFS 5–9) had 
both an increased risk of mortality and longer duration of 
hospital stay compared with patients who were not frail 
(appendix pp 3–5). Frailty did not appear to be associated 
with any specific subgroup (eg, those aged ≥80 years).
Discussion
The COPE study was designed to provide urgent and 
much needed evidence on the effect of frailty in adult 
patients admitted to hospital with COVID-19. Our data 
show that the prevalence of frailty (CFS 5–8) was 49·4% 
and that frailty was associated with both earlier death 
and longer time spent in hospital. These outcomes 
worsened with increasing frailty, with similar findings 
after adjustment for age and comorbidity.
These data show that the prevalence of frailty, using the 
clinical frailty scale, was slightly higher than expected for 
a European hospital population.11,12 The first of these 
studies suggested prevalence of frailty to be 39·6% in a 
large (n=12 282) but single centre UK estimate,12 the 
second suggested frailty to be 42% in a much younger 
population drawn from the 500 000-person UK Biobank.11 
However, the varying degree of frailty across the sites in 
our study appears consistent with the natural variation 
expected. Our findings suggest that contracting 
COVID-19 is probably more severe for frail people and 
adds empirical substance to the widely held belief that a 
poor outcome is associated with increased age or 
increased frailty.
Mortality in our population was 27·2%, which is in line 
with current mortality estimates for COVID-19 globally. 
In a large patient cohort in New York (NY, USA) 555 (21%) 
of 2634 people died;3 the participants had a median age of 
63 years (estimated IQR 49–74) compared with a median 
age of 74 years (61–83) in our study.3 The mortality rate in 
our study is slightly lower than that reported in the 
original patient characterisation from Wuhan, China 
(28·3%),4 which was also a younger population, with a 
median age of 56 years (46–67, range 18–87). Additionally, 
Docherty and colleagues21 recently reported a mortality 
rate of 26% (6769 of 20 133 participants) in a large UK 
descriptive study. The median age of their population 
was 73 years (IQR 58–82). Their findings are similar to 
ours and probably the same impact of frailty would be 
observed within their larger cohort.
These data also show that frailty helps to predict the risk 
of death in patients with COVID-19, similar to in other 
diseases.6,19 The primary aim of this study was to provide 
evidence to support clinicians in making decisions about 
appropriate allocation of health-care resources in the 
urgent setting of the COVID-19 pandemic. Notably, the 
decision support tool recom mended for use in the UK 
National Health Service includes the CFS that is used in 
this study.8 These results support the use of the CFS in the 
decision making process and it could be considered for 
adoption in other countries.
Time from hospital admission to discharge was 
significantly longer in frail patients (CFS 5–6 and 
CFS 7–9) than in patients with low frailty scores. Again, 
findings are consistent with the non-COVID-19 literature, 
and further support the hypothesis that frailty is an 
appropriate tool for use in patients with COVID-19. Also, 
people with high frailty scores probably require longer to 
recover and rehabilitate from COVID-19 and require 
more complex discharge planning,22 but these were not 
assessed in this study. Notably, frailty should not be used 
alone for clinical decisions.23
These data were collected from representative hos-
pitals situated across England, Scotland, and Wales. 10% 
of participants were from Italy, which adds to the wider 
European generalisability. However, incidence of 
COVID-19 tended to appear in hotspots around the 
Figure 3: Time to discharge from hospital by CFS
CFS=clinical frailty score.
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country and caution should be used until the pandemic 
has been analysed across countries worldwide. The 
demographic findings, such as the increased mortality 
associated with increased C-reactive protein levels and 
prevalence of comorbidities (hypertension, diabetes, and 
coronary artery disease) are also in line with other 
estimates, suggesting that our data are comparable with 
other populations.2,3 It is unfortunate that because of the 
constraints of the pandemic, we were unable to rapidly 
collect more clinical data, for example body-mass index. 
We deliberately focused only on core variables within the 
study and group to achieve rapid reporting of frailty data. 
Further, as data regarding the pandemic become more 
widely available, comorbidities are being shown to be of 
increasing importance, so these additional data would 
have added value to the manuscript but were not readily 
available at the time of data collection. The study data 
quality and completeness allowed all analyses to include 
at least of 97% of included patients.
It is possible that inaccuracies might have occurred 
during data collection; however, training in data 
collection was provided to all study personnel and the 
research team are experienced in collecting observational 
data in frail people from multiple UK sites.6,19
The UK guidelines recommend frailty assessment 
using the CFS in the COVID-19 pandemic.8 The CFS is a 
simple, quick, and easy-to-use frailty measure, although 
not well validated in people younger than 65 years or 
those with learning disabilities.9 Other frailty measures 
are available for inpatient frailty assessment but are 
usually longer to complete or rely on routinely collected 
data to calculate the frailty score.14,24 With scarce research 
evidence, we did not feel it appropriate to analyse other 
frailty assessments, despite their potential usefulness 
during this pandemic. This study also provides evidence 
regarding the validated use of the CFS in the frailty 
assessment of people with COVID-19.
Another limitation is that patients were only included 
if admitted to hospital. This criterion will have excluded 
patients that were discharged from or died in emergency 
departments, and excluded cases diagnosed in the com-
munity, who did not present to secondary care. It will 
also have excluded many frailer individuals living 
in residential and nursing facilities. Hence, these 
findings are only generalisable to an inpatient 
population.
This study, which was designed to assess the effect of 
frailty on outcomes in people of all ages with COVID-19, 
showed that frailty increases risk of mortality, even after 
accounting for age and other known comorbidities linked 
to COVID-19. Overall, these findings support the use of 
frailty as a trigger for specialist resource allocation, 
pathway decision aid, and in shared decision making 
in people with COVID-19. The findings show the 
importance of frailty assessment, rather than age, in 
combination with other measures in the context of 
COVID-19.
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